title: In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.
abstract: The 2013 LEADER surveillance program monitored the in vitro activity of linezolid and comparator agents against Gram-positive bacteria at 60 medical centers in the United States. A total of 7183 pathogens were contributed from 6 predetermined pathogen groups. The groups were Staphylococcus aureus, coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae, β-hemolytic streptococci, and viridans group streptococci. The MIC90 value for each of the 6 pathogen groups was 1 μg/mL. Susceptibility of "all organisms" to linezolid was 99.83%. Only 12 isolates (2 S. aureus, 3 Staphylococcus epidermidis, 1 Streptococcus sanguinis, 5 Enterococcus faecium, and 1 Enterococcus faecalis) were nonsusceptible to linezolid (0.17%). Three of these (2 S. aureus and 1 E. faecium) harbored the cfr resistance mechanism. The findings indicate that linezolid activity remains stable, although there are examples of clonal dissemination within several monitored institutions.
authors: JMI Laboratories, North Liberty, IA 52317, USA. Electronic address: robert-flamm@jmilabs.com.
authors: Robert K
authors: RK
authors: Flamm
authors: JMI Laboratories, North Liberty, IA 52317, USA.
authors: Rodrigo E
authors: RE
authors: Mendes
authors: Pfizer Inc, Collegeville, PA 19426, USA.
authors: Patricia A
authors: PA
authors: Hogan
authors: JMI Laboratories, North Liberty, IA 52317, USA.
authors: James E
authors: JE
authors: Ross
authors: JMI Laboratories, North Liberty, IA 52317, USA; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
authors: David J
authors: DJ
authors: Farrell
authors: JMI Laboratories, North Liberty, IA 52317, USA; Tufts University School of Medicine, Boston, MA 02111, USA.
authors: Ronald N
authors: RN
authors: Jones
mesh_terms: D000046:Academic Medical Centers; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D016983:Enterococcus / Q000187:drug effects* / Q000302:isolation & purification; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006801:Humans; D000069349:Linezolid / Q000494:pharmacology*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013210:Staphylococcus / Q000187:drug effects* / Q000302:isolation & purification; D013291:Streptococcus / Q000187:drug effects* / Q000302:isolation & purification; D014481:United States; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000069349:Linezolid
keywords: LEADER; Linezolid; Oxazolidinones